Astrazeneca Pharma India Ltd vs Hindustan Bio Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 14, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8350 as of 14 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 80.7 on March 2021 to 185.9 on March 2025 . This represents a CAGR of 18.16% over 5 yearsThe P/E Ratio of Hindustan Bio Sciences Ltd changed from 120.8 on March 2024 to 69.8 on March 2025 . This represents a CAGR of -23.99% over 2 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 7525 crore on March 2021 to ₹ 21515 crore on March 2025 . This represents a CAGR of 23.38% over 5 yearsThe Market Cap of Hindustan Bio Sciences Ltd changed from ₹ 15.38 crore on March 2021 to ₹ 7.16 crore on March 2025 . This represents a CAGR of -14.18% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 618.18 crore as compare to the Sep '25 revenue of ₹ 565.26 crore. This represent the growth of 9.36% The revenue of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0.4 crore as compare to the Sep '25 revenue of ₹ 0.01 crore. This represent the growth of 3900% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 51.44 crore as compare to the Sep '25 ebitda of ₹ 76.06 crore. This represent the decline of -32.37% The ebitda of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0.09 crore as compare to the Sep '25 ebitda of ₹ -0.05 crore. This represent the decline of -280% The net profit of Astrazeneca Pharma India Ltd changed from ₹ -11.79 crore to ₹ 32.59 crore over 7 quarters. This represents a CAGR of NaN% The net profit of Hindustan Bio Sciences Ltd changed from ₹ 0.08 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of 0.00% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Hindustan Bio Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Limited was initially incorporated as Garuda Cements Limited in December 1991.
Earlier, it was engaged in cement manufacturing and due to sluggish in the industry, the Company diversified its business into Bio Technology & Pharmaceuticals activities in 2000-01 and the name was changed from Garuda Cements Limited to Hindustan Bio-Sciences Limited.
In 2002, it diversified into software field and subsequently changed its name to Hindustan Bio Sciences Limited on August 8, 2002. The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified businesses in pharmaceutical and biotechnology industries.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Hindustan Bio Sciences Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Hindustan Bio Sciences Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,930 Cr while Market cap of Hindustan Bio Sciences Ltd is 9 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Hindustan Bio Sciences Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Hindustan Bio Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Hindustan Bio Sciences Ltd?

As of May 14, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8372.2. On the other hand, Hindustan Bio Sciences Ltd stock price is INR ₹8.79.

How do dividend payouts of Astrazeneca Pharma India Ltd and Hindustan Bio Sciences Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Hindustan Bio Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.